Does Small Fibre Neuropathy predict Charcot Neuroarthropathy?

  • Research type

    Research Study

  • Full title

    Does small fibre neuropathy (SFN) predict the development and progression of Charcot neuroarthropathy (CN) bone and joint destruction - a pilot study.

  • IRAS ID

    329752

  • Contact name

    Ines Reichert

  • Contact email

    i.reichert@nhs.net

  • Sponsor organisation

    King's College Hospital Trust

  • Clinicaltrials.gov Identifier

    n/a, n/a

  • Duration of Study in the UK

    0 years, 7 months, 1 days

  • Research summary

    Acute Charcot Neuroarthropathy (CN) may accompany severe diabetes and is a devastating, hyperinflammatory condition, often leading to bone and joint destruction and foot deformity requiring amputation. Acute CN usually presents with a hot swollen foot. However, the condition is largely painless due to peripheral neuropathy causing loss of sensation of the skin. Hence the diagnosis is often missed or delayed.
    Diagnosis is currently based on experienced clinical assessment and a raised temperature of the limb. Radiographs often do not show any changes early. Treatment consists of plaster, a total contact cast, until the temperature normalises, which might last several months to a year.
    We propose to improve the diagnosis and monitoring of the disease process by measuring molecules in the blood, bone / joint fluid and skin which are related to nerve dysfunction. Peripheral neuropathy, including insensate skin, is regarded as the key problem. Related neuronal markers are neurotrophin Nerve Growth Factor (NGF) and the neuropeptides Calcitonin-Gene related peptide (CGRP) and substance P (SP).
    We previously collected bone and blood samples in a few patients with acute and chronic CN) and found these markers elevated in patients with acute neuroarthropathy. We would like to follow up these findings with a prospective study comparing patients with acute and chronic diabetic CN and no diabetes.
    The study will be conducted at a specialist centre seeing a large number of patients with diabetic CN. Bone / joint and blood samples are taken regularly on the standard treatment pathway. The study will require additional 5-10ml blood. Bone samples taken during routine biopsy in clinic or as waste tissue during surgery. The study aims to reach results after about one year.
    The results may inform novel pathways to diagnose and monitor the course of acute CN, and thus guide early treatment which will be a real advance for patients.

  • REC name

    South Central - Hampshire B Research Ethics Committee

  • REC reference

    26/SC/0270

  • Date of REC Opinion

    4 Aug 2026

  • REC opinion

    Favourable Opinion